A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease
This clinical trial investigates an experimental medicine called trontinemab. It is being developed as a potential treatment for Alzheimer's disease. A major hurdle in treating brain conditions is getting medicines through the body's natural protective barrier into the brain. Trontinemab is designed to cross this barrier more effectively. In this early Phase 1 study, researchers want to see how the drug distributes throughout the brain, where it binds, and how long it remains in brain tissue. The trial is open to both healthy volunteers and people living with Alzheimer's disease who are 18 years of age or older. Participants will receive the study medicine and undergo detailed brain imaging and health checks. While early studies do not guarantee direct health improvements, the results will help scientists understand whether trontinemab could be a safe, effective option for treating Alzheimer's in the future.
At a glance
What is this study about?
Alzheimer's disease is a condition that slowly affects memory, thinking, and daily abilities. One of the greatest challenges in treating Alzheimer's is that the brain has a natural protective shield called the blood-brain barrier. While this barrier keeps harmful substances out, it also stops most medicines from getting into the brain where they are needed.
Trontinemab is a new type of laboratory-made protein, known as a monoclonal antibody. It has been specially designed using new technology to 'sneak' across the blood-brain barrier. Once inside, it aims to find and attach to specific proteins linked to Alzheimer's disease.
This early-stage research study, known as a Phase 1 trial, is looking closely at how trontinemab behaves inside the human body. Doctors want to see how much of the drug gets into the brain, where it settles, and how long it stays there before clearing out. To understand this, researchers are studying the drug in both healthy adult volunteers and individuals with Alzheimer's disease.
Finding answers to these questions is a crucial step in drug discovery. By learning how trontinemab moves and acts in real people, scientists can decide the best doses to test and find out whether this drug has the potential to slow down or treat Alzheimer's disease in larger future trials.
Key takeaways
- Tests an experimental drug called trontinemab designed to reach inside the brain.
- Open to both healthy volunteers and people with Alzheimer's disease aged 18 and older.
- Aims to find out how the drug moves, where it binds, and how long it stays in the brain.
- Involves health checks, receiving the study drug, and specialised brain scans.
- Participation is entirely voluntary and you can withdraw at any time.
Who may be eligible?
This study is open to adults aged 18 and older. Because this is an early-stage study looking at how a medicine works in the body, researchers are looking for two groups of people: healthy volunteers who do not have memory problems, and individuals who have been diagnosed with Alzheimer's disease.
To take part, participants will need to undergo initial health screenings. These checks ensure that it is safe for you to receive the study drug and complete specialised brain scans. People with certain serious medical conditions, or those who cannot safely have brain scans (such as people with certain metal implants), may not be able to join.
If you have Alzheimer's disease, you may need a study partner—such as a family member or caregiver—who can attend appointments with you and help answer questions about your health and daily routine.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged 18 or older.
- You are either in good general health OR have a diagnosis of Alzheimer's disease.
- You are comfortable attending regular clinic appointments and having blood tests.
- You are able to safely undergo brain imaging scans (such as MRI or PET scans).
- If needed, you have a family member or caregiver willing to support you at visits.
What does participation involve?
Taking part in this trial involves several hospital or clinic visits. At the start, the study team will carry out health checks, such as blood tests, heart tracings (ECGs), and physical exams to make sure you are suitable. You will receive the study drug, trontinemab, typically given through a drip into a vein (an intravenous infusion). Researchers will use specialised brain scans, such as PET or MRI scans, to take pictures of your brain and track where the medicine travels. You will also have regular follow-up visits and blood samples taken so doctors can check your wellbeing, monitor any side effects, and see how quickly the medicine leaves your system. The trial team will tell you the exact number of visits and the full study duration before you agree to join.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is trontinemab?
Trontinemab is an experimental antibody medicine designed to cross into the brain more easily to target proteins linked with Alzheimer's disease.
Why are healthy volunteers included in an Alzheimer's study?
Comparing healthy brains with brains affected by Alzheimer's helps scientists see clear differences in how the drug travels, binds, and clears from the body.
Will taking part cure my Alzheimer's disease?
No. This is an early-stage study focused on safety and how the drug reaches the brain, rather than proving whether it cures or slows the disease.
Do I have to pay to take part in this trial?
No, you do not pay for clinical trial medicines or tests. Clinical trials often cover reasonable travel expenses as well.
What happens if I decide I want to stop?
You can leave the study at any point. Your decision will not affect the standard of care you receive from your regular doctors or the NHS.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.